SI9500220B - Vodne formulacije risperidona - Google Patents

Vodne formulacije risperidona Download PDF

Info

Publication number
SI9500220B
SI9500220B SI9500220A SI9500220A SI9500220B SI 9500220 B SI9500220 B SI 9500220B SI 9500220 A SI9500220 A SI 9500220A SI 9500220 A SI9500220 A SI 9500220A SI 9500220 B SI9500220 B SI 9500220B
Authority
SI
Slovenia
Prior art keywords
solution
solution according
range
water
risperidone
Prior art date
Application number
SI9500220A
Other languages
English (en)
Slovenian (sl)
Other versions
SI9500220A (en
Inventor
Marc Karel Jozef Francois
Willy Maria Albert Carlo Dries
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26955530&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI9500220(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SI9500220A publication Critical patent/SI9500220A/sl
Publication of SI9500220B publication Critical patent/SI9500220B/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SI9500220A 1994-07-11 1995-07-10 Vodne formulacije risperidona SI9500220B (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/272,462 US5453425A (en) 1994-07-11 1994-07-11 Risperidone oral formulation
US08/429,435 US5616587A (en) 1994-07-11 1995-04-26 Aqueous risperidone formulations

Publications (2)

Publication Number Publication Date
SI9500220A SI9500220A (en) 1996-02-29
SI9500220B true SI9500220B (sl) 2004-12-31

Family

ID=26955530

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9500220A SI9500220B (sl) 1994-07-11 1995-07-10 Vodne formulacije risperidona

Country Status (37)

Country Link
US (3) US5453425A (ja)
EP (1) EP0769965B1 (ja)
JP (1) JP2872412B2 (ja)
KR (1) KR100212942B1 (ja)
CN (1) CN1148226C (ja)
AP (1) AP774A (ja)
AT (1) ATE206931T1 (ja)
AU (1) AU684193B2 (ja)
BG (1) BG63070B1 (ja)
BR (1) BR9508253A (ja)
CA (1) CA2194564C (ja)
CY (1) CY2268B1 (ja)
CZ (1) CZ285204B6 (ja)
DE (1) DE69523313T2 (ja)
DK (1) DK0769965T3 (ja)
EE (1) EE03426B1 (ja)
ES (1) ES2165918T3 (ja)
FI (1) FI116510B (ja)
HK (1) HK1010691A1 (ja)
HR (1) HRP950397B1 (ja)
HU (1) HU222352B1 (ja)
IL (1) IL114525A (ja)
MX (1) MX9700374A (ja)
MY (1) MY114389A (ja)
NO (1) NO320366B1 (ja)
NZ (1) NZ289432A (ja)
PH (1) PH31626A (ja)
PL (1) PL179972B1 (ja)
PT (1) PT769965E (ja)
RO (1) RO116778B1 (ja)
RU (1) RU2161965C2 (ja)
SI (1) SI9500220B (ja)
SK (1) SK282159B6 (ja)
TR (1) TR199500778A1 (ja)
TW (1) TW420615B (ja)
WO (1) WO1996001652A1 (ja)
ZA (1) ZA955720B (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE288270T1 (de) * 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
UA72189C2 (uk) 1997-11-17 2005-02-15 Янссен Фармацевтика Н.В. Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
US6682758B1 (en) 1998-12-22 2004-01-27 The United States Of America As Represented By The Department Of Health And Human Services Water-insoluble drug delivery system
US6495164B1 (en) 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
US20060148826A1 (en) * 2002-08-23 2006-07-06 Ashish Gogia Stable aqueous solutions of risperidone and methods for their preparation
EP1615923A1 (en) * 2003-04-22 2006-01-18 Synthon B.V. Risperidone monohydrochloride
PE20050285A1 (es) 2003-06-24 2005-06-09 Novartis Ag Composicion farmaceutica que comprende analogos ciclicos de somatostatina
US20050036977A1 (en) * 2003-08-11 2005-02-17 Dilip Gole Taste-masked resinate and preparation thereof
ES2245252B1 (es) * 2004-06-15 2007-03-01 Farmalider, S.A. Solucion acuosa de risperidona para administracion oral.
ES2245891B1 (es) * 2004-07-09 2006-11-16 Clinmet S.L. "metodo para la obtencion de un excipiente universal para la administracion oral de principios activos farmaceuticos y composiciones de excipientes resultantes del metodo".
WO2006129160A2 (en) * 2005-06-01 2006-12-07 Aurobindo Pharma Limited Stable aqueous oral solution of risperidone
DE602006005423D1 (de) * 2005-06-29 2009-04-16 Verisfield Uk Ltd Pharmazeutische Zusammensetzungen von Risperidon in wässriger Lösung
US8852638B2 (en) 2005-09-30 2014-10-07 Durect Corporation Sustained release small molecule drug formulation
JP4922657B2 (ja) * 2006-05-09 2012-04-25 高田製薬株式会社 リスペリドン経口用液剤
WO2007138462A2 (en) * 2006-06-01 2007-12-06 Wockhardt Ltd Aqueous oral formulations of risperidone
BRPI0811319A2 (pt) 2007-05-25 2015-02-10 Tolmar Therapeutics Inc Composição fluida, método de formação de uma composição fluida, implante biodegrádavel formado in situ, método de formação de um implante biodegradável in situ, kit, implante e método de trataento
US7776866B2 (en) * 2007-09-15 2010-08-17 Protia, Llc Deuterium-enriched risperidone
EP3909585A1 (en) * 2007-12-19 2021-11-17 Janssen Pharmaceutica NV Dosing regimen associated with long acting injectable paliperidone esters
EP2389187B1 (en) 2009-01-20 2016-11-16 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Sorbic and benzoic acid and derivatives thereof enhance the activity of a neuropharmaceutical
GB2513060B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
CA2850707C (en) * 2011-10-03 2023-03-21 The University Of Utah Research Foundation Application of 5-ht6 receptor antagonists for the alleviation of cognitive deficits of down syndrome
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US11000520B2 (en) 2014-11-07 2021-05-11 Indivior Uk Limited Buprenorphine dosing regimens
CA3027297A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
RU2022101542A (ru) 2016-06-13 2022-02-03 Сайньюрекс Интернэшнл (Тайвань) Корп. Сокристаллы бензоата лития и их применения
KR20190066608A (ko) * 2016-09-23 2019-06-13 델포어, 인코포레이티드 소분자 치료제 화합물 조성물
US11369579B2 (en) 2016-10-24 2022-06-28 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
RU2646812C1 (ru) * 2016-10-24 2018-03-07 Общество с ограниченной ответственностью "Трейдсервис" Жидкая лекарственная форма рисперидона и способ ее получения
US10336679B2 (en) 2016-10-24 2019-07-02 Syneurx International (Taiwan) Corp. Polymorphic forms of sodium benzoate and uses thereof
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
CN107260662A (zh) * 2017-06-21 2017-10-20 南京正科医药股份有限公司 一种利培酮口服溶液及其制备方法
CN107441037A (zh) * 2017-08-16 2017-12-08 南京正科医药股份有限公司 一种利培酮口服溶液
CN109589304A (zh) * 2017-10-01 2019-04-09 万特制药(海南)有限公司 利培酮口服溶液及其制备方法
US10098861B1 (en) 2017-10-24 2018-10-16 Syneurx International (Taiwan) Corp. Pharmaceutical composition comprising sodium benzoate compound and clozapine, and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4337261A (en) * 1980-07-28 1982-06-29 Hoechst-Roussel Pharmaceuticals Inc. (1,2-Benzisoxazol)phenoxyacetic acids as diuretics
IL88233A (en) * 1987-11-03 1993-08-18 Genentech Inc Gamma interferon formulation
FR2641278B1 (fr) * 1989-01-05 1991-03-22 Lipha Piperidines, procedes de preparation et medicaments les contenant
DK203990D0 (da) * 1990-08-24 1990-08-24 Novo Nordisk As Piperazinylderivater
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
US5453425A (en) * 1994-07-11 1995-09-26 Janssen Pharmaceutica N.V. Risperidone oral formulation
FR2796273B1 (fr) * 1999-07-15 2003-09-12 Oreal Composition a phase grasse liquide gelifiee par un polyamide a groupements ester terminaux

Also Published As

Publication number Publication date
HUT76826A (en) 1997-11-28
IL114525A (en) 1999-06-20
PL179972B1 (pl) 2000-11-30
JP2872412B2 (ja) 1999-03-17
HK1010691A1 (en) 1999-06-25
ZA955720B (en) 1997-01-10
ES2165918T3 (es) 2002-04-01
AU2927595A (en) 1996-02-09
PT769965E (pt) 2002-04-29
DE69523313T2 (de) 2002-06-27
CZ285204B6 (cs) 1999-06-16
EE9700009A (et) 1997-08-15
SK282159B6 (sk) 2001-11-06
IL114525A0 (en) 1995-11-27
MX9700374A (es) 1997-04-30
KR970704472A (ko) 1997-09-06
KR100212942B1 (ko) 1999-08-02
USRE39181E1 (en) 2006-07-11
CN1155247A (zh) 1997-07-23
AU684193B2 (en) 1997-12-04
EE03426B1 (et) 2001-06-15
NO970051L (no) 1997-01-07
ATE206931T1 (de) 2001-11-15
EP0769965A1 (en) 1997-05-02
EP0769965B1 (en) 2001-10-17
JPH09511751A (ja) 1997-11-25
US5616587A (en) 1997-04-01
TW420615B (en) 2001-02-01
CY2268B1 (en) 2003-07-04
TR199500778A1 (tr) 1996-10-21
FI970109A (fi) 1997-01-10
US5453425A (en) 1995-09-26
CA2194564A1 (en) 1996-01-25
SI9500220A (en) 1996-02-29
RO116778B1 (ro) 2001-06-29
CA2194564C (en) 1997-12-16
WO1996001652A1 (en) 1996-01-25
BG63070B1 (bg) 2001-03-30
FI116510B (fi) 2005-12-15
HU222352B1 (hu) 2003-06-28
DE69523313D1 (de) 2001-11-22
PL318132A1 (en) 1997-05-12
AP9700910A0 (en) 1997-01-31
PH31626A (en) 1999-01-12
NO970051D0 (no) 1997-01-07
HRP950397B1 (en) 2002-04-30
NO320366B1 (no) 2005-11-28
RU2161965C2 (ru) 2001-01-20
MY114389A (en) 2002-10-31
HRP950397A2 (en) 1997-10-31
BG101106A (en) 1997-08-29
FI970109A0 (fi) 1997-01-10
DK0769965T3 (da) 2002-02-04
NZ289432A (en) 1998-05-27
CN1148226C (zh) 2004-05-05
SK2297A3 (en) 1997-09-10
HU9700082D0 (en) 1997-02-28
AP774A (en) 1999-10-28
CZ2797A3 (en) 1997-07-16
BR9508253A (pt) 1997-12-23

Similar Documents

Publication Publication Date Title
SI9500220B (sl) Vodne formulacije risperidona
US5024997A (en) Palatable ibuprofen solutions
ES2215223T3 (es) Suspensiones liquidas de sabor enmascarado.
CA1320192C (en) Pharmaceutical compositions
AU776609B2 (en) Topical suspension formulations containing ciprofloxacin and dexamethasone
RU97102139A (ru) Водные композиции рисперидона
AU706027B2 (en) Pharmaceutical composition for oral administration of flavonoids
TW349870B (en) An antifungal pharmaceutical composition for oral administration and a process for the preparation thereof
CA2478411C (en) Palatable oral suspension and method
ES2347536T3 (es) Composiciones particuladas de axetil cefuroxima revestidas.
PT92271B (pt) Processo para a obtencao de preparacoes efervescentes de ibuprofeno
RU96123917A (ru) Пероральные жидкие композиции, содержащие алендронат
CA2452638A1 (en) Optimised formulation of tobramycin for aerosolization
CA2392050A1 (en) Pharmaceutical formulations containing zolmitriptan
AU638484B2 (en) Non-effervescent ibuprofen compositions
CA2234426A1 (en) Antibacterial composition for oral administration
ZA894828B (en) Process for the preparation of anti-inflammatory pharmaceutical agents with an ibuprofen base,with elimination,in solution,of the bitter taste,burning of the throat and intestinal toxicity
ES2235834T3 (es) Matriz directamente comprimible para la liberacion controlada de dosis diarias unicas de claritromicina.
US5422102A (en) Antiinflammatory and analgesic gel preparation
US20040241235A1 (en) Granules and granules coated with a masked taste
DK175752B1 (da) Flydende oralt farmaceutisk diclofenacpræparat og fremgangsmåde til fremstilling deraf
US4076804A (en) Erythromycin therapy
SK100998A3 (en) Pharmaceutical compositions of cilansetron stabilized against racemisation
JPH0717863A (ja) プラノプロフェン点眼液
US5696095A (en) Pharmaceutical formulations of spiramycin

Legal Events

Date Code Title Description
OU02 Decision according to article 73(2) ipa 1992, publication of decision on partial fulfilment of the invention and change of patent claims

Effective date: 20041103

IF Valid on the event date